Avivagen Announces U.S. Product Launch of Vivamune for Cats
20 Agosto 2013 - 9:00AM
Access Wire
OTTAWA, ONTARIO, August 20, 2013
- Avivagen Inc. (TSXV:VIV), a wellness
company developing and delivering products that support and enhance
the health and quality of life for animals and the people who care
for them, announces its United States launch of Vivamune(TM) Health
Chews for cats.
Avivagen is pleased to announce the
launch of its latest product - Vivamune(TM) Health Chews for cats.
Now U.S. pet parents have direct access to this exciting new
feline health supplement. The proprietary
ingredients in Vivamune(TM) Health Chews have been shown to act on
the immune system and may thereby support healthy skin, coat and
gut and help to maintain normal mobility. This science-based and
highly-palatable natural chew is intended to help cats lead long
and healthy lives.
U.S. pet parents can order Vivamune(TM)
Health Chews for their cats online at www.vivamunehealth.com.
Dave Hankinson, Executive Director of Avivagen,
commented on this important milestone, "For some time our customers
have asked us when Avivagen was going to introduce a product for
cats comparable to our Vivamune(TM) product for dogs. After putting
in the necessary time and effort to develop a formulation suitable
for cats, it is exciting to introduce our product for this
important companion animal species, further broadening access to
Avivagen's health discoveries."
Cameron Groome, CEO and President of Avivagen,
remarked, "The launch of Vivamune(TM) Health Chews for cats is an
important milestone for Avivagen: It is gratifying to bring forward
a further product that meets our customers' needs and at the same
time provides a further source of revenues for Avivagen. In the
coming quarters we will continue to drive sales of our three
commercial products, Vivamune(TM) Health Chews, Oximunol(TM)
Chewable Tablets and OxC-beta for livestock."
About Avivagen Inc.
Avivagen Inc. is a publicly-listed life
sciences company trading on the TSX Venture Exchange under the
ticker symbol "VIV". The Company's goal is to
develop and deliver scientifically-proven solutions that can truly
benefit companion and production animals by employing natural
mechanisms for maintaining good health. Avivagen's targeted markets
include Pet Wellness and Livestock Productivity.
The company has sites located in
partnership facilities of the National Research Council of Canada
(NRC) - in Ottawa, Ontario and Charlottetown, Prince Edward
Island.
More information can be found at
www.avivagen.com.
About
OxC-beta
Avivagen's
proprietary and patent-protected technology is based on its
discoveries concerning carotenoid antioxidants. The novel natural
compounds discovered by Avivagen support the body's own systems to
maintain and enhance health, particularly by supporting immune
function. Avivagen's commercial-stage application of its technology
is Fully-Oxidized beta-Carotene (OxC-beta).
OxC-beta compounds occur naturally as
carotenoid oxidation products in vegetation, but in minute amounts.
They have been developed to support the health of companion animals
and for use in the global food animal market.
Research results indicate OxC-beta
supports innate immune function, which can help maintain good
health. In pets, OxC-beta supports overall vitality and energy,
mobility and joint function, skin, coat and gut. Results observed
in food animals have included healthier growth, better utilization
of feed and decreased mortality. In food animals, it is intended
that use of OxC-beta avoids the feeding of antibiotics.
The commercial products of Avivagen
are Oximunol(TM) Chewables, OxC-beta for
livestock and Vivamune(TM) Health
Chews.
About
Vivamune(TM) Health Chews -
"For dogs that dig life" and "extraordinary cats"
Vivamune(TM) Health Chews are
scientifically-formulated chews for dogs and cats that
contain Avivagen's proprietary active
ingredients. Vivamune(TM) Health Chews work with a pet's own immune
system to maintain overall health and well-being. They are sold in
re-sealable packages of 30 chews and are currently available in the
United States by ordering on-line at www.vivamunehealth.com.
About Oximunol(TM)
Chewables - "Optimized Health in a Chewable Tablet"
Oximunol(TM) Chewables
are scientifically-formulated chewable tablets that
contain Avivagen's proprietary, patented active ingredient
OxC-beta. OxC-beta has been shown to stimulate innate cellular
immunity and may thereby help to maintain overall health and
well-being. Oximunol(TM) Chewables are available through
veterinarians for dogs of all ages in the United States.
About OxC-beta for Livestock
OxC-beta for Livestock is available as a 10% pre-mix
sold in 1.0 or 5.0 Kg quantities for parts-per-million addition to
animal feeds, in accordance with producer-developed protocols. In
prior studies, OxC-beta has been shown to support health and growth
in species such as fish, chicken, pigs and cattle. OxC-beta for
livestock is currently available for commercial sale in the Kingdom
of Thailand.
Forward
Looking Statements
This
news release includes certain forward-looking statements that are
based upon current expectations, which involve risks and
uncertainties associated with the business of Avivagen Inc. and the
environment in which the business operates. Any statements
contained herein that are not statements of historical facts may be
deemed to be forward-looking, including those identified by the
expressions "will", "anticipate", "believe", "plan", "estimate",
"expect", "intend", and similar expressions. The forward-looking
statements reflect the current expectations of Avivagen Inc.
regarding future results or events. These forward-looking
statements are subject to a number of risks and uncertainties that
could cause actual results or events to differ materially from
current expectations. Avivagen assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those reflected in the forward-looking
statements.
Neither TSX
Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
For more
information:
Avivagen Inc.
Cameron Groome
CEO & President
Phone: 613-949-8164
c.groome@avivagen.com
Avivagen (TSXV:VIV)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Avivagen (TSXV:VIV)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024